Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1

Danson, S. J. and Johnson, P. and Ward, T. H. and Dawson, M. and Denneny, O. and Dickinson, G. and Aarons, L. and Watson, A. and Jowle, D. and Cummings, J. and Robson, L. and Halbert, Gavin and Dive, C. and Ranson, M. (2011) Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. Annals of Oncology, 22 (7). pp. 1653-1660. ISSN 1569-8041

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

This trial describes a first-in-man evaluation of RH1, a novel bioreductive drug activated by DT-diaphorase (DTD), an enzyme overexpressed in many tumours. A dose-escalation phase I trial of RH1 was carried out. The primary objective was to establish the maximum tolerated dose (MTD) of RH1. Secondary objectives were assessment of toxicity, pharmacokinetic determination of RH1 and pharmacodynamic assessment of drug effect through measurement of DNA cross linking in peripheral blood mononuclear cells (PBMCs) and tumour, DTD activity in tumour and NAD(P)H:quinone oxidoreductase 1 (NQO1) polymorphism status. Eighteen patients of World Health Organization performance status of zero to one with advanced refractory solid malignancies were enrolled. MTD was 1430 mu g/m(2)/day with reversible bone marrow suppression being dose limiting. Plasma pharmacokinetic analysis showed RH1 is rapidly cleared from blood (t(1/2) = 12.3 min), with AUC increasing proportionately with dose. The comet-X assay demonstrated dose-related increases in DNA cross linking in PBMCs. DNA cross linking was demonstrated in tumours, even with low levels of DTD. Only one patient was homozygous for NQO1 polymorphism precluding any conclusion of its effect. RH1 was well tolerated with predictable and manageable toxicity. The MTD of 1430 mu g/m(2)/day is the dose recommended for phase II trials. The biomarkers of DNA cross linking, DTD activity and NQO1 status have been validated and clinically developed.

Item type: Article
ID code: 34673
Keywords: chemotherapy, DT-diaphorase, pharmacodynamic, pharmacokinetic, phase I, RH1, nadph cytochrome-P450 reductase, DNA cross-linking, antitumor quinones, cell-lines, oxidoreductases, NAD(P)H, agent, cytotoxicity, activation, Pharmacy and materia medica, Oncology, Hematology
Subjects: Medicine > Pharmacy and materia medica
Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Technology and Innovation Centre > Continuous Manufacturing and Crystallisation (CMAC)
Related URLs:
    Depositing user: Pure Administrator
    Date Deposited: 17 Oct 2011 15:49
    Last modified: 05 Sep 2014 12:12
    URI: http://strathprints.strath.ac.uk/id/eprint/34673

    Actions (login required)

    View Item